Key result
ACE and ACE2 functional gene polymorphisms may impact the predisposition, course, and outcome of major pulmonary diseases, including COVID-19, revealing their potential utility as biomarkers.
Why the study?
Chronic and acute respiratory diseases pose major public health problems with mostly symptomatic treatments, and the impact of ACE and ACE2 functional gene polymorphisms across major pulmonary diseases requires examination.
Do ACE and ACE2 gene polymorphisms impact the predisposition, course, and outcome of major pulmonary diseases?
Do ACE and ACE2 gene polymorphisms impact the predisposition, course, and outcome of major pulmonary diseases?
ACE and ACE2 gene polymorphisms have potential utility as genetic markers and biomarkers for disease predisposition, course, and outcome in major pulmonary diseases, including COVID-19.
Answers are grounded in this paper and cite their sources.
Supports investigation of ACE/ACE2 polymorphisms as biomarkers in pulmonary disease; leaves open their clinical utility pending validation.
Chronic and acute respiratory diseases pose a major problem for public health worldwide due to the high morbidity and mortality rates, while treatment options remain mostly symptomatic. The renin-angiotensin system (RAS) plays an important role in lung tissue, regulating pulmonary circulation and blood pressure, but also contributing to normal pulmonary function and development. Angiotensin-converting enzyme (ACE) and its homologous angiotensin-converting enzyme 2 (ACE2) are considered to be amongst the main RAS regulators and are highly expressed in the pulmonary vascular endothelium. This review discusses the impact of ACE and ACE2 functional gene polymorphisms on seven major pulmonary diseases, in terms of predisposition, course, and outcome, revealing their potential utility as both genetic markers and biomarkers. The discussed conditions include chronic obstructive pulmonary disease (COPD), pulmonary hypertension (PH), asthma, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), lung cancer and pulmonary sarcoidosis (PS), as well as SARS-CoV-2 viral infection and COVID-19 disease.
No takes yet. Share an insight, caveat, or question.
Gintoni et al. (2021) conducted a review in Pulmonary diseases including COVID-19. ACE and ACE2 functional gene polymorphisms was evaluated. ACE and ACE2 functional gene polymorphisms may impact the predisposition, course, and outcome of major pulmonary diseases, including COVID-19, revealing their potential utility as biomarkers.
Synapse has enriched 10 related papers. Consider them for comparative context: